Oncolytics Biotech® Exhibits Collective Translational Data, Showcasing Pelareorep's Efficacy Against Various Cancer Types
In a groundbreaking development, Oncolytics Biotech Inc., a clinical-stage company specialising in immunotherapy for oncology, is making strides in the fight against cancer with their product, pelareorep. This systemically delivered oncolytic virus has shown remarkable potential in treating immunotherapy-resistant cancers.
Pelareorep works by selectively replicating in cancer cells, leading to direct cell lysis, and stimulating immune activation. This dual mechanism transforms immune-resistant tumors into targets susceptible to immune-mediated destruction. The virus achieves this by driving T cell expansion and tumor infiltration, boosting cytotoxic T-cell activity, and increasing PD-L1 expression.
Translational research indicates that pelareorep promotes an inflamed tumor phenotype, converting 'cold' tumors into 'hot' ones that are responsive to immune attack. This conversion has been observed in various studies, including those focusing on metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- breast cancer.
In mPDAC, clinical trials report rare but significant 2-year overall survival rates exceeding 20% when pelareorep is combined with chemotherapy, compared to below 10% with chemotherapy alone. In HR+/HER2- metastatic breast cancer, pelareorep combined with standard chemotherapy extended median overall survival by more than 10 months, alongside improved progression-free survival. A small study combining pelareorep with chemotherapy and checkpoint inhibitors even demonstrated a 62% objective response rate, highlighting its capacity to overcome resistance and enhance immunotherapy efficacy.
Safety data from over 1,100 patients across several tumor types indicate that pelareorep has a favorable safety profile, with mostly manageable, transient flu-like symptoms as the common adverse events. Regulatory agencies, including the FDA, have recognised pelareorep's potential by granting Fast Track designations.
Oncolytics Biotech Inc. is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. The company is also planning combination clinical trials with pelareorep in solid malignancies.
However, it is important to note that the press release contains forward-looking statements, which involve risks and uncertainties that could cause actual results to differ from those in the statements. These risks and uncertainties include, but are not limited to, the successful completion of clinical trials, the receipt of regulatory approvals, and market acceptance of pelareorep.
For more information, please refer to the original press release or visit Oncolytics Biotech Inc.'s website. The company's logo and contact information for investor relations and media are also included in the press release.
In summary, pelareorep's unique mechanism of action, combined with its promising clinical results, positions it as a potential game-changer in the treatment of immunotherapy-resistant cancers.
- The groundbreaking development in cancer treatment, pelareorep, not only replicates selectively in cancer cells but also stimulates immune activation, potentially revolutionizing medical-conditions like cancer in the field of health-and-wellness.
- Remarkable news emerged about a study focusing on metastatic pancreatic ductal adenocarcinoma (mPDAC), showing that pelareorep combined with chemotherapy yielded rare but significant 2-year overall survival rates exceeding 20%, highlighting its potential effectiveness in combating this condition.
- In a scientific breakthrough, pelareorep has been found to drive T cell expansion and tumor infiltration, increasing PD-L1 expression, making traditionally hard-to-treat cold tumors more susceptible to immune-mediated destruction - a finding that could significantly impact the news and treatment of various medical-conditions, including cancer.
